Patents by Inventor Johann Peter Morsdorf

Johann Peter Morsdorf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic form of doxazosin mesylate (form III)
    Patent number: 6140334
    Abstract: A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 8.49.degree., 11.72.degree., 16.03.degree., 18.29.degree., 21.03.degree., 22.87.degree. and 25.02.degree.. Owing to its crystalline properties, the new form of doxazosin mesylate according to the invention has surprising advantages both with regard to its synthesis and for pharmaceutical processing into solid dosage forms. A process for preparing the new form of doxazosin mesylate and pharmaceutical compositions comprising the new form of doxazosin mesylate are also described.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: October 31, 2000
    Assignee: Heumann Pharma GmbH
    Inventors: Johann Peter Morsdorf, Ingomar Grafe
  • Polymorphic form of doxazosin mesylate (form II)
    Patent number: 6133269
    Abstract: A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 10.68.degree., 14.45.degree., 17.37.degree., 23.45.degree., 23.82.degree. and 24.30 .degree.. Owing to its crystalline properties, the new form of doxazosin mesylate according to the invention has surprising advantages both with regard to its synthesis and for pharmaceutical processing into solid dosage forms. A process for preparing the new form of doxazosin mesylate and pharmaceutical compositions comprising the new form of doxazosin mesylate are also described.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: October 17, 2000
    Assignee: Heumann Pharma GmbH
    Inventors: Johann Peter Morsdorf, Ingomar Grafe
  • Polymorphic form of doxazosin mesylate (Form I)
    Patent number: 6130218
    Abstract: A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 15.40.degree., 16.85.degree., 18.06.degree., 24.15.degree. and 25.81.degree.. Owing to its crystalline properties, the new form of doxazosin mesylate according to the invention has surprising advantages both with regard to its synthesis and for pharmaceutical processing into solid dosage forms. A process for preparing the new form of doxazosin mesylate and pharmaceutical compositions comprising the new form of doxazosin mesylate are also described.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: October 10, 2000
    Assignee: Heumann Pharma GmbH
    Inventors: Johann Peter Morsdorf, Ingomar Grafe
  • Crystalline trimetrexate salts and the process for making the same
    Patent number: 6017921
    Abstract: The present invention provides for a crystalline form of trimetrexate either as a glucuronate, acetate, hydrochloride, methanosulfonate or lactate salt, which can be processed galenically as a stable, well-defined solid substance and processes for producing the crystalline forms. Such crystalline forms allow for prolonged stability in storage and for oral and intravenous administration of the drug.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: January 25, 2000
    Assignee: U.S. Bioscience, Inc.
    Inventors: Paul Kennedy, Ingomar Grafe, Johann Peter Morsdorf, Kurt-Henning Ahrens
  • Crystalline trimetrexate salts and the process for making the same
    Patent number: 5716960
    Abstract: The present invention provides for a crystalline form of trimetrexate either as a glucuronate, acetate, hydrochloride, methanosulfonate or lactate salt, which can be processed galenically as a stable, well-defined solid substance and processes for producing the crystalline forms. Such crystalline forms allow for prolonged stability in storage and for oral and intravenous administration of the drug.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: February 10, 1998
    Assignee: U.S. Bioscience Inc. and Individuals
    Inventors: Paul Kennedy, Ingomar Grafe, Johann Peter Morsdorf, Kurt-Henning Ahrens